Pub. Date : 2018 Feb
PMID : 29251327
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | Sorafenib | AKT serine/threonine kinase 1 | Homo sapiens |
| 2 | Significantly decreased AKT Ser473 phosphorylation in HCC cells, and conversely enhanced phosphorylation of AKT Ser473 and mTORC2 in CCC cells, were observed with sorafenib treatment. | Sorafenib | AKT serine/threonine kinase 1 | Homo sapiens |
| 3 | Significantly decreased AKT Ser473 phosphorylation in HCC cells, and conversely enhanced phosphorylation of AKT Ser473 and mTORC2 in CCC cells, were observed with sorafenib treatment. | Sorafenib | AKT serine/threonine kinase 1 | Homo sapiens |
| 4 | Simultaneous administration of everolimus to suppress activated mTORC1 in RBE cells revealed that combined everolimus and sorafenib treatment under mTORC2 disassembly could enhance growth inhibition through the suppression of both sorafenib- and everolimus-dependent AKT Ser473 phosphorylation in addition to the inhibition of mTORC1 phosphorylation. | Sorafenib | AKT serine/threonine kinase 1 | Homo sapiens |
| 5 | Prevention of escape by AKT/mTOR signaling from the RAF/MEK/ERK pathway in sorafenib treatment by suppressing mTORC2 activity may lead to promising new approaches in CCC therapy. | Sorafenib | AKT serine/threonine kinase 1 | Homo sapiens |